Evaluation of new technologies for cancer control based on population trends in disease incidence and mortality
MetadataShow full item record
Cancer interventions often disseminate in the population before evidence of their effectiveness is available. Population disease trends provide a natural experiment for assessing the characteristics of the disease and the potential impact of the intervention. We review models for extracting information from population data for use in economic evaluations of cancer screening interventions. We focus particularly on prostate-specific antigen (PSA) screening for prostate cancer and describe approaches that can be used to project the likely costs and benefits of competing screening policies. Results indicate that the lifetime probability of biopsy-detectable prostate cancer is 33%, the chance of clinical diagnosis without screening is 13%, and the average time from onset to clinical diagnosis is 14 years. Less aggressive screening policies that screen less often and use more conservative criteria (e.g., higher PSA thresholds) for biopsy referral may dramatically reduce PSA screening costs with modest impact on benefit. © The Author 2013. Published by Oxford University Press. All rights reserved.
Showing items related by title, author, creator and subject.
Interval Colorectal Cancer Incidence Among Subjects Undergoing Multiple Rounds of Fecal Immunochemical Testingvan der Vlugt, M.; Grobbee, E.; Bossuyt, P.; Bos, A.; Bongers, E.; Spijker, W.; Kuipers, E.; Lansdorp_Vogelaar, Iris; Spaander, M.; Dekker, E. (2017)© 2017 AGA Institute Background & Aims Among subjects screened for colorectal cancer (CRC) by the guaiac fecal occult blood test, interval cancers develop in 48% to 55% of the subjects. Data are limited on how many ...
Christou, Aliki; Katzenellenbogen, Judith; Thompson, Sandra (2010)Background. Despite a lower incidence of bowel cancer overall, Indigenous Australians are more likely to be diagnosed at an advanced stage when prognosis is poor. Bowel cancer screening is an effective means of reducing ...
Personalizing age of cancer screening cessation based on comorbid conditions: Model estimates of harms and benefitsLansdorp_Vogelaar, Iris; Gulati, R.; Mariotto, A.; Schechter, C.; De Carvalho, T.; Knudsen, A.; Van Ravesteyn, N.; Heijnsdijk, E.; Pabiniak, C.; Van Ballegooijen, M.; Rutter, C.; Kuntz, K.; Feuer, E.; Etzioni, R.; De Koning, H.; Zauber, A.; Mandelblatt, J. (2014)Background: Harms and benefits of cancer screening depend on age and comorbid conditions, but reliable estimates are lacking. Objective: To estimate the harms and benefits of cancer screening by age and comorbid conditions ...